Azeliragon structure
|
Common Name | Azeliragon | ||
---|---|---|---|---|
CAS Number | 603148-36-3 | Molecular Weight | 532.116 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 667.7±65.0 °C at 760 mmHg | |
Molecular Formula | C32H38ClN3O2 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 357.6±34.3 °C |
Use of AzeliragonTTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).Target: RAGEin vitro: TTP488 is an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction. Chronic oral dosing of TTP488 in AD transgenic mice led to a reduction of amyloid load in the brain, improves performance on behavioral testing and normalization of electrophysiological recordings from hippocampal slices.[1]in vivo: The small molecule RAGE antagonist, TTP488, is developed by Trans-Tech Pharma. The TTP488 or control peptide is administered i.p. daily at a dose of 100 mcg/d.[3] Successful use of the RAGE inhibitor TTP488 in Phase II testing has led to a Phase III clinical trial for AD patients.[2] |
Name | 1-Propanamine, 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl |
---|---|
Synonym | More Synonyms |
Description | TTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).Target: RAGEin vitro: TTP488 is an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction. Chronic oral dosing of TTP488 in AD transgenic mice led to a reduction of amyloid load in the brain, improves performance on behavioral testing and normalization of electrophysiological recordings from hippocampal slices.[1]in vivo: The small molecule RAGE antagonist, TTP488, is developed by Trans-Tech Pharma. The TTP488 or control peptide is administered i.p. daily at a dose of 100 mcg/d.[3] Successful use of the RAGE inhibitor TTP488 in Phase II testing has led to a Phase III clinical trial for AD patients.[2] |
---|---|
Related Catalog | |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 667.7±65.0 °C at 760 mmHg |
Molecular Formula | C32H38ClN3O2 |
Molecular Weight | 532.116 |
Flash Point | 357.6±34.3 °C |
Exact Mass | 531.265259 |
PSA | 39.52000 |
LogP | 8.98 |
Vapour Pressure | 0.0±2.0 mmHg at 25°C |
Index of Refraction | 1.572 |
Storage condition | 2~8°C |
~% Azeliragon CAS#:603148-36-3 |
Literature: Hari, Anitha Patent: US2008/249316 A1, 2008 ; Location in patent: Page/Page column 6 ; |
Precursor 2 | |
---|---|
DownStream 0 |
[3-(4-{2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1H-imidazole-4-yl}-phenoxy)-propyl]-diethyl-amine |
1-Propanamine, 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl- |
3-(4-{2-Butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethyl-1-propanamine |
3-(hydroxymethyl)phenylboronic acid pinacol ester |
UNII:LPU25F15UQ |
3-(4-{2-Butyl-1-[4-(4-chlorphenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethylpropan-1-amin |
3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl alcohol |
Azeliragon |
[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanol |
[3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine |
3-(4-{2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethylpropan-1-amine |
TTP488 |